« Back
Home /
Mal-PEG2-Gly-Gly-Phe-Gly-Exatecan

Mal-PEG2-Gly-Gly-Phe-Gly-Exatecan

Item no.	HY-153795-5mg
Manufacturer	MedChem Express
CASRN	1599439-54-9
Amount	5 mg
Quantity options	10 mg 25 mg 5 mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	99.09
Citations	[1]Masuda Takeshi, et al. Preparation of antibody-drug conjugates for cancer therapy. Patent WO2014057687.
Smiles	O=C(C=CC1=O)N1CCC(NCCOCCOCCC(NCC(NCC(N[C@@H](CC2=CC=CC=C2)C(NCC(NCCCC(N[C@@H]3C4=C5C(C(N6C5)=CC([C@](O)(C(OC7)=O)CC)=C7C6=O)=NC8=CC(F)=C(C)C(CC3)=C84)=O)=O)=O)=O)=O)=O)=O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Shipping Condition	Cool pack
Available
Manufacturer - Type	ADC Related
Manufacturer - Applications	Cancer-programmed cell death
Manufacturer - Targets	Drug-Linker Conjugates for ADC; Topoisomerase
Shipping Temperature	Blue Ice
Storage Conditions	-20°C (Powder, protect from light, stored under nitrogen)
Molecular Weight	1149.18
Product Description	Mal-PEG2-Gly-Gly-Phe-Gly-Exatecan is a drug-linker conjugate for ADC. Mal-PEG2-Gly-Gly-Phe-Gly-Exatecan consists of Exatecan (HY-13631) and a linker. Mal-PEG2-Gly-Gly-Phe-Gly-Exatecan can be used for synthesis of ADCs and for cancer research[1].
Manufacturer - Research Area	Cancer
Solubility	DMSO: 100 mg/mL (ultrasonic)
Manufacturer - Pathway	Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage
Isoform	Camptothecins
Clinical information	No Development Reported

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-153795-5mg-safety-datasheet.pdf